Clinical Care Options - Oncology CME - The Right Care for the Younger Patient: Meeting the Needs of Adolescents and Young Adults With Cancer

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe the physical and psychosocial challenges facing the AYA cancer patient
• Suggest the most suitable treatment strategy for individual AYA patients with cancer based on current evidence
• Apply current evidence to select treatment centers (adult or pediatric) that optimize treatment for AYA patients

Clinical Care Options - Oncology CME - An Update on Early Breast Cancer

webcasts (3) prIME Oncology - after official ESMO: Evolving Strategies in the Management of Advanced Ovarian Cancer (Italy/US/Spain)

Topics
Topic 1 Defining the rationale and role for targeted therapy in ovarian cancer Nicoletta Colombo, MD Topic 2 Targeting angiogenesis: Where are we in 2010? Robert A. Burger, MD, FACOG, FACS Topic 3 Beyond antiangiogenesis: What are the options? Andres Poveda, MD

A prIME Oncology educational activity held after the official ESMO program hours: Evolving Strategies in the Management of Advanced Ovarian Cancer Oct

Topic 1—	Defining the rationale and role for targeted therapy in ovarian cancer Nicoletta Colombo, MD
Topic 2—	Targeting angiogenesis: Where are we in 2010? Robert A. Burger, MD, FACOG, FACS
Topic 3—	Beyond antiangiogenesis: What are the options? Andres Poveda, MD This Webcast contains video and downloadable slides from our symposium “Evolving Strategies in the Management of Advanced Ovarian Cancer,” a prIME Oncology educational activity that was held after the official ESMO program hours on Monday, 11 October in Milan, Italy.

Ovarian Cancer Tweets about........ selected slide re: OCATS/Regina conference

Clinical Care Options Oncology - Truth and Consequences: Antiangiogenic Therapies in Cancer

.

CCO Treatment Updates Truth and Consequences: Antiangiogenic Therapies in Cancer Virtual Presentation Truth and Consequences: Antiangiogenic Therapies in Cancer Faculty: Robert S. Kerbel, PhD Release Date: July 02, 2010 Expiration Date: July 01, 2011 Robert S. Kerbel, PhD, reviews the latest preclinical and clinical findings on the use of angiogenesis inhibitors to treat cancer, including mechanisms of resistance, the relevance of tumor flare-up after discontinuation of antiangiogenic therapy, and potential markers to predict clinical benefit. Learning Objectives Upon completion of this activity, participants should be able to: Describe the mechanisms of targeting angiogenesis Explain the mechanisms of resistance to antiangiogenic drugs Describe the phenomenon of rebound or tumor flare that may result from the discontinuation of antiangiogenic therapy Evaluate data supporting the use of angiogenesis inhibitors in the neoadjuvant, adjuvant, and metastatic settings Assess the potential clinical role of biomarkers of response to antiangiogenic therapy Truth and Consequences: Antiangiogenic Therapies in Cancer Download slides on the latest preclinical and clinical findings on the use of angiogenesis inhibitors to treat cancer, including mechanisms of resistance, the relevance of tumor flare-up after discontinuation of antiangiogenic therapy, and potential markers to predict clinical benefit. Format: Microsoft PowerPoint (.ppt) | File size: 8.61 MB | Date posted: 7/2/2010 . Jointly Sponsored by USF Health and Clinical Care Options, LLC.

Gyn Clinical Spotlights | slides/interviews: Dr's Fleming, Monk, Birrer

7 JUNE 2010
		These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release: #LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States. View the Primary Expert Analysis with Gini Fleming, MD, and Bradley Monk, MD, and access downloadable slides View the Supplemental Perspectives and Discussion with Bradley Monk, MD, and Michael Birrer, MD, PhD, and access downloadable slides

full free access: Clinical Care Options Oncology - Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer (slides)

>

Clinical Care Options Oncology - Slideset: Research Update on PARP Inhibition: Emerging Data in Breast, Ovarian, and Other Cancers

Source: Research Update on PARP Inhibition: Emerging Data in Breast, Ovarian, and Other Cancers

William J. Gradishar, MD, FACP, reviews the mechanism of PARP inhibition and its rationale as a therapeutic pathway and describes recent data using novel PARP inhibitors.

To download for use as a self-study resource or in your own noncommercial talks.

Download slides on recent data in PARP inhibitors in breast, ovarian, and other solid tumors.


*You must be logged into the clinicaloptions.com site to view or save the slides. (free)

Users are encouraged to use these slides in their own presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent. These slides may not be published or posted online without permission from Clinical Care Options.

EPGM-Munich - Expert Practice in Gynecologic Oncology - free access

There are a number of slide presentations (free full access)